US FDA warns 30 telehealth firms over misleading marketing of compounded GLP‑1 drugs
The U.S. Food and Drug Administration has warned 30 telehealth companies for making false or misleading claims about compounded versions of GLP‑1 drugs, the agency said on Tuesday.
More info
